FY2025 EPS Estimates for BioSyent Increased by Bloom Burton

BioSyent Inc. (CVE:RX) – Analysts at Bloom Burton lifted their FY2025 earnings per share estimates for BioSyent in a report issued on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.81 per share for the year, up from their previous forecast of $0.80. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.94 EPS.

BioSyent Stock Performance

Shares of CVE RX opened at C$11.20 on Tuesday. The stock has a 50 day moving average price of C$11.04 and a 200 day moving average price of C$11.11. BioSyent has a 52 week low of C$8.24 and a 52 week high of C$12.13. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The stock has a market capitalization of C$128.10 million, a PE ratio of 18.18 and a beta of 0.93.

Insiders Place Their Bets

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of BioSyent stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Corporate insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.